Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
2496 | 3914 | 27.4 | 56% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
5 | 4 | CHEMISTRY, ORGANIC//CHEMISTRY, INORGANIC & NUCLEAR//CHEMISTRY, MULTIDISCIPLINARY | 1745167 |
346 | 3 | CARDIOTOXICITY//ANTHRACYCLINES//CAMPTOTHECIN | 36072 |
2496 | 2 | IFOSFAMIDE//CHEMOSENSITIVITY TEST//MESNA | 3914 |
5913 | 1 | CHEMOSENSITIVITY TEST//HISTOCULTURE DRUG RESPONSE ASSAY//CHEMOSENSITIVITY | 1559 |
6772 | 1 | IFOSFAMIDE//MESNA//TROFOSFAMIDE | 1445 |
20094 | 1 | MELPHALAN//CHLORAMBUCIL//PREDNIMUSTINE | 476 |
27547 | 1 | THIOTEPA//THIOTEPA MERCAPTURATE//N N N TRIETHYLENEPHOSPHORAMIDE | 227 |
31462 | 1 | CELL MED//H1 CELLS//L15F10 MEDIUM | 152 |
37538 | 1 | HETEROCYCLIC TRIOXIRANES//TEROXIRONE//HUMAN NON SMALL CELL LUNG CANCER CELLS | 55 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | IFOSFAMIDE | authKW | 596226 | 7% | 28% | 269 |
2 | CHEMOSENSITIVITY TEST | authKW | 225137 | 1% | 53% | 54 |
3 | MESNA | authKW | 206307 | 2% | 42% | 63 |
4 | TROFOSFAMIDE | authKW | 159765 | 1% | 79% | 26 |
5 | BNP7787 | authKW | 124795 | 0% | 100% | 16 |
6 | OXAZAPHOSPHORINES | authKW | 120955 | 1% | 57% | 27 |
7 | CHLOROACETALDEHYDE | authKW | 117107 | 1% | 52% | 29 |
8 | GLUFOSFAMIDE | authKW | 110925 | 0% | 89% | 16 |
9 | CELL MED | address | 86804 | 0% | 70% | 16 |
10 | HISTOCULTURE DRUG RESPONSE ASSAY | authKW | 81504 | 0% | 58% | 18 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Oncology | 36827 | 50% | 0% | 1961 |
2 | Pharmacology & Pharmacy | 5340 | 23% | 0% | 910 |
3 | Chemistry, Medicinal | 426 | 4% | 0% | 151 |
4 | Toxicology | 333 | 4% | 0% | 139 |
5 | Hematology | 331 | 4% | 0% | 142 |
6 | Chemistry, Analytical | 302 | 5% | 0% | 208 |
7 | CYTOLOGY & HISTOLOGY | 205 | 0% | 0% | 15 |
8 | Obstetrics & Gynecology | 159 | 3% | 0% | 108 |
9 | Medicine, Research & Experimental | 158 | 4% | 0% | 141 |
10 | Urology & Nephrology | 158 | 3% | 0% | 103 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | CELL MED | 86804 | 0% | 70% | 16 |
2 | CHEMOSENSITIVITATESTUNGEN | 23399 | 0% | 100% | 3 |
3 | NIOMECH | 23399 | 0% | 100% | 3 |
4 | CIHR GSK CHAIR PAEDIAT CLIN PHARMACOL | 17721 | 0% | 45% | 5 |
5 | SLOTERVAART HOSP | 17591 | 1% | 11% | 20 |
6 | CLIN PHARMACOL BIOANAL | 17548 | 0% | 75% | 3 |
7 | KRIGO | 17548 | 0% | 75% | 3 |
8 | CLIN PHARMACOL TOXICOL PHARMACOKINET | 15599 | 0% | 100% | 2 |
9 | MICHAEL DARMADY | 12475 | 0% | 40% | 4 |
10 | INT BIOANAL BUSINESS SUPPORT | 10398 | 0% | 67% | 2 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | CANCER CHEMOTHERAPY AND PHARMACOLOGY | 54602 | 6% | 3% | 227 |
2 | INTERNATIONAL JOURNAL OF CELL CLONING | 17293 | 1% | 7% | 31 |
3 | EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY | 16345 | 2% | 3% | 63 |
4 | CANCER TREATMENT REPORTS | 14853 | 2% | 3% | 65 |
5 | RECENT RESULTS IN CANCER RESEARCH | 14246 | 1% | 6% | 31 |
6 | ANTI-CANCER DRUGS | 8797 | 2% | 2% | 61 |
7 | CANCER RESEARCH | 7502 | 5% | 1% | 197 |
8 | BRITISH JOURNAL OF CANCER | 5896 | 3% | 1% | 118 |
9 | ANTICANCER RESEARCH | 5139 | 3% | 1% | 114 |
10 | HUMAN CELL | 4065 | 0% | 5% | 10 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | IFOSFAMIDE | 596226 | 7% | 28% | 269 | Search IFOSFAMIDE | Search IFOSFAMIDE |
2 | CHEMOSENSITIVITY TEST | 225137 | 1% | 53% | 54 | Search CHEMOSENSITIVITY+TEST | Search CHEMOSENSITIVITY+TEST |
3 | MESNA | 206307 | 2% | 42% | 63 | Search MESNA | Search MESNA |
4 | TROFOSFAMIDE | 159765 | 1% | 79% | 26 | Search TROFOSFAMIDE | Search TROFOSFAMIDE |
5 | BNP7787 | 124795 | 0% | 100% | 16 | Search BNP7787 | Search BNP7787 |
6 | OXAZAPHOSPHORINES | 120955 | 1% | 57% | 27 | Search OXAZAPHOSPHORINES | Search OXAZAPHOSPHORINES |
7 | CHLOROACETALDEHYDE | 117107 | 1% | 52% | 29 | Search CHLOROACETALDEHYDE | Search CHLOROACETALDEHYDE |
8 | GLUFOSFAMIDE | 110925 | 0% | 89% | 16 | Search GLUFOSFAMIDE | Search GLUFOSFAMIDE |
9 | HISTOCULTURE DRUG RESPONSE ASSAY | 81504 | 0% | 58% | 18 | Search HISTOCULTURE+DRUG+RESPONSE+ASSAY | Search HISTOCULTURE+DRUG+RESPONSE+ASSAY |
10 | ISOPHOSPHORAMIDE MUSTARD | 70904 | 0% | 91% | 10 | Search ISOPHOSPHORAMIDE+MUSTARD | Search ISOPHOSPHORAMIDE+MUSTARD |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | KERBUSCH, T , DE KRAKER, J , KEIZER, HJ , VAN PUTTEN, JWG , GROEN, HJM , JANSEN, RLH , SCHELLENS, JHM , BEIJNEN, JH , (2001) CLINICAL PHARMACOKINETICS AND PHARMACODYNAMICS OF IFOSFAMIDE AND ITS METABOLITES.CLINICAL PHARMACOKINETICS. VOL. 40. ISSUE 1. P. 41 -62 | 134 | 83% | 62 |
2 | ZHANG, J , TIAN, Q , CHAN, SY , LI, SC , ZHOU, SF , DUAN, W , ZHU, YZ , (2005) METABOLISM AND TRANSPORT OF OXAZAPHOSPHORINES AND THE CLINICAL IMPLICATIONS.DRUG METABOLISM REVIEWS. VOL. 37. ISSUE 4. P. 611 -703 | 203 | 37% | 95 |
3 | GIRAUD, B , HEBERT, G , DEROUSSENT, A , VEAL, GJ , VASSAL, G , PACI, A , (2010) OXAZAPHOSPHORINES: NEW THERAPEUTIC STRATEGIES FOR AN OLD CLASS OF DRUGS.EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY. VOL. 6. ISSUE 8. P. 919 -938 | 96 | 73% | 24 |
4 | DE JONGE, ME , HUITEMA, ADR , RODENHUIS, S , BEIJNEN, JH , (2005) CLINICAL PHARMACOKINETICS OF CYCLOPHOSPHAMIDE.CLINICAL PHARMACOKINETICS. VOL. 44. ISSUE 11. P. 1135-1164 | 107 | 66% | 116 |
5 | BAUMANN, F , PREISS, R , (2001) CYCLOPHOSPHAMIDE AND RELATED ANTICANCER DRUGS.JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES. VOL. 764. ISSUE 1-2. P. 173 -192 | 94 | 74% | 57 |
6 | WAGNER, T , (1994) IFOSFAMIDE CLINICAL PHARMACOKINETICS.CLINICAL PHARMACOKINETICS. VOL. 26. ISSUE 6. P. 439-456 | 77 | 88% | 69 |
7 | HOFFMAN, RM , (1993) IN-VITRO ASSAYS FOR CHEMOTHERAPY SENSITIVITY.CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY. VOL. 15. ISSUE 2. P. 99-111 | 94 | 81% | 15 |
8 | HOFFMAN, RM , (1991) INVITRO SENSITIVITY ASSAYS IN CANCER - A REVIEW, ANALYSIS, AND PROGNOSIS.JOURNAL OF CLINICAL LABORATORY ANALYSIS. VOL. 5. ISSUE 2. P. 133-143 | 87 | 82% | 73 |
9 | ZHANG, J , TIAN, Q , ZHU, YZ , XU, AL , ZHOU, SF , (2006) REVERSAL OF RESISTANCE TO OXAZAPHOSPHORINES.CURRENT CANCER DRUG TARGETS. VOL. 6. ISSUE 5. P. 385-407 | 112 | 41% | 6 |
10 | BODDY, AV , YULE, SM , (2000) METABOLISM AND PHARMACOKINETICS OF OXAZAPHOSPHORINES.CLINICAL PHARMACOKINETICS. VOL. 38. ISSUE 4. P. 291 -304 | 72 | 67% | 105 |
Classes with closest relation at Level 2 |